Assessment of Elemental Impurities Level After Multiple Administration of DWJ1230 or DWB2001 in Subjects With Functional Diarrhea or Irritable Bowel Syndrome With Predominant Diarrhea.

An Open-label, Randomized, Multiple Dose, Parallel Study to Assess Elemental Impurities Level After Multiple Administration of DWJ1230 or DWB2001 in Subjects With Functional Diarrhea or Irritable Bowel Syndrome With Predominant Diarrhea(IBS-D)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05816681

Enrollment

Registered

2023-04-18

Start date

2022-08-22

Completion date

2023-04-10

Last updated

2023-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diarrhea

Brief summary

This study aims to assess elemental impurities level after dministration of dioctahedral smectite in subjects with functional diarrhea or irritable bowel syndrome with predominant diarrhea. Male or female subjects aged between 19 and 60 years will participate in the study. The study design is an opne-label, randomized, multiple dose paraller study. The patients were randomly assigned to DWJ1230 or DWB2001. It is intended that a total of 60 subjects will be enrolled to ensure that at least 24 subjects will complete the study.

Interventions

DRUGDWJ1230

Daewoong Pharmaceutical

DRUGDWB2001

Daewoong Bio

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Subjects with chronic functional Diarrhea. (included Irritable Bowel Syndrome with perdominant diarrhea(IBS-D)). * Male or Female subjects aged between 19 and 60 years at screening. * Body Mass Index(BMI) between 18 and 27kg/m2 in male, 17 and 26kg/m2 in female. ※ BMI (kg/m2) = body weight (kg)/\[height (m)\]2 * Subjects who voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a sufficient explanation on this study and fully understanding the information.

Exclusion criteria

* No history or clinically significant symptoms or severe disease, including cardiac, neurological, pulmonary, hepatic, biliary, gastrointestinal, endocrinologic, or renal disorders, or cancer. * Identified or strongly suspected organic cause to diarrhea. * Celiac disease or Intestinal malabsorption, Unspecified intestinal malabsorption. * History of any serious adverse reaction or adverse event or hypersensitivity to any component of investigational product. * Constipation, Iron deficiency anaemia, Hypocalcaemia, Osteoporosis. * Known domestic, leisure or professional exposure to elemental impurities. * Women who are breastfeeding or are planning to become pregnant during the study. * Positive pregnancy test at screening. * Presence of clinically significant physical, laboratory, vital signs, or ECG findings. * Blood lead level \> 3.3 μg/dL(=33.0 μg/L) at screening. * galactose intolerance, fructose intolerance, Lapp lactase deficiency, sucurase-isomaltase deficiency, glucose-galactose malabsorption. * Receipt of any investigational agent or study drug within 4 weeks prior to screening. * Patients with history of alcohol or drug abuse. * Subjects who donated whole blood within 2 months, donated blood components within 1 month. * Subjects who have participated and taken investigational drug within 1 month prior to study drug administration. * Subjects who the investigator considers inappropriate for the study due to other reasons.

Design outcomes

Primary

Measure	Time frame
To assess the concentration of lead in blood after administration of Investigational Product	Day 7

Secondary

Measure	Time frame
To assess blood concentration of other Class I(Cadmium, Arsenic, Mercury) after administration of Investigational Product	Day 7
To assess blood concentration of other Class IIa(Cobalt, Nickel) and of aluminium after administration of Investigational Product	Day 7

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026